A Phase 1b, Open Label, Dose Escalation Study of IOA-289, an Orally Bioavailable, Selective Autotaxin (ENPP2) Inhibitor Alone and in Combination With Gemcitabine/Nab-paclitaxel in Patients With Metastatic Pancreatic Cancer
Latest Information Update: 12 Jun 2024
At a glance
- Drugs Gemcitabine (Primary) ; IOA 289 (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Acronyms AION-01
- Sponsors iOnctura
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 04 Mar 2024 Planned End Date changed from 17 Apr 2024 to 1 Feb 2025.
- 04 Mar 2024 Planned primary completion date changed from 17 Oct 2023 to 1 Dec 2024.